Global Depression Screening Mental Health Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Disease Type;

Anxiety, Mood Disorders, Depression, Bipolar Disorders, Psychotic Disorders, and Eating Disorders.

By Diagnosis;

Psychological Test, Lab Tests, and Depression Screening Tests.

By Treatment;

Medication, Brain-Stimulation Treatments, and Substance Abuse Treatment.

By End User;

Hospitals & Clinics, Medical Research Centers, and Academic Institutes.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn191524584 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Depression Screening Mental Health Market (USD Million), 2021 - 2031

In the year 2024, the Global Depression Screening Mental Health Market was valued at USD 740.19 million. The size of this market is expected to increase to USD 1,122.23 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.1%.

The Global Depression Screening Mental Health Market is witnessing significant growth as awareness of mental health issues continues to rise globally. Depression, a leading cause of disability, affects millions of individuals, prompting healthcare systems to prioritize early detection and intervention. Screening for depression is crucial in identifying individuals who may be at risk, facilitating timely access to appropriate treatment and support. This growing recognition of the importance of mental health screening is driving investments in innovative screening tools and methodologies across various healthcare settings.

As the stigma surrounding mental health diminishes, more individuals are seeking help, which is further propelling the demand for effective screening solutions. The integration of mental health services into primary care settings has also gained momentum, enabling healthcare providers to identify and address depression alongside other medical conditions. Advancements in technology, including digital platforms and telehealth services, are transforming the landscape of mental health screening, making it more accessible and efficient. These developments not only enhance the reach of screening initiatives but also improve the overall quality of care provided to patients.

Government initiatives and increased funding for mental health programs are creating a conducive environment for the growth of the depression screening market. With an emphasis on preventive care and holistic treatment approaches, healthcare systems are adopting comprehensive strategies to address mental health issues. As a result, the Global Depression Screening Mental Health Market is poised for expansion, offering numerous opportunities for stakeholders, including healthcare providers, technology developers, and policymakers, to contribute to a more robust mental health framework that prioritizes early detection and effective management of depression.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Disease Type
    2. Market Snapshot, By Diagnosis
    3. Market Snapshot, By Treatment
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Global Depression Screening Mental Health Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Depression
        2. Growing Awareness of Mental Health Issues
        3. Government Initiatives and Support for Mental Health
      2. Restraints
        1. Stigma Associated with Mental Health
        2. Limited Access to Mental Health Services
        3. Inadequate Training of Healthcare Providers
      3. Opportunities
        1. Expansion of Telehealth and Remote Screening
        2. Innovative Digital Mental Health Solutions
        3. Increased Investment in Mental Health Research
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Depression Screening Mental Health Market, By Disease Type, 2021 - 2031 (USD Million)
      1. Anxiety
      2. Mood Disorders
      3. Depression
      4. Bipolar Disorders
      5. Psychotic Disorders
      6. Eating Disorders
    2. Global Depression Screening Mental Health Market, By Diagnosis, 2021 - 2031 (USD Million)
      1. Psychological Test
      2. Lab Tests
      3. Depression Screening Tests
    3. Global Depression Screening Mental Health Market, By Treatment, 2021 - 2031 (USD Million)
      1. Medication
      2. Brain-Stimulation Treatments
      3. Substance Abuse Treatment
    4. Global Depression Screening Mental Health Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals & Clinics
      2. Medical Research Centers
      3. Academic Institutes
    5. Global Depression Screening Mental Health Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Johnson & Johnson Services Inc.
      2. AstraZeneca
      3. Bristol-Myers Squibb Company
      4. Lilly
      5. F. Hoffmann-La Roche Ltd.
      6. Novartis AG
      7. Otsuka Holdings Co., Ltd.
      8. Pfizer Inc.
      9. GSK plc
      10. Janssen Global Services LLC
      11. Meiji Holdings Co., Ltd
      12. Abbott
      13. Jazz Pharmaceuticals Inc.
      14. AbbVie Inc.
  7. Analyst Views
  8. Future Outlook of the Market